Clinical Trial Update: Intralesional Antimony for Bolivian Cutaneous Leishmaniasis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating intralesional antimony for Bolivian cutaneous leishmaniasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis
• Leishmaniasis

Drugs mentioned

• Antimony (antimony compound)

Snippet

Sponsor: Fundacion Nacional de Dermatologia | Conditions: Leishmaniasis, Cutaneous Leishmaniasis | Phase 2 | Status: COMPLETED